158 related articles for article (PubMed ID: 24291818)
41. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
[TBL] [Abstract][Full Text] [Related]
42. Expression of TNKS1 is correlated with pathologic grade and Wnt/β-catenin pathway in human astrocytomas.
Tang B; Wang J; Fang J; Jiang B; Zhang M; Wang Y; Yang Z
J Clin Neurosci; 2012 Jan; 19(1):139-43. PubMed ID: 22154485
[TBL] [Abstract][Full Text] [Related]
43. Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl) phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights.
Quintina Peters X; Poonan P; Salifu Yakubu E; Issa Alahmdi M; Abo-Dya NE; Soliman M
Curr Pharm Biotechnol; 2023 Mar; ():. PubMed ID: 37005548
[TBL] [Abstract][Full Text] [Related]
44. Tankyrase-1 Ankyrin Repeats Form an Adaptable Binding Platform for Targets of ADP-Ribose Modification.
Eisemann T; McCauley M; Langelier MF; Gupta K; Roy S; Van Duyne GD; Pascal JM
Structure; 2016 Oct; 24(10):1679-1692. PubMed ID: 27594684
[TBL] [Abstract][Full Text] [Related]
45. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
[TBL] [Abstract][Full Text] [Related]
46. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
[TBL] [Abstract][Full Text] [Related]
47. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939.
Kirby CA; Cheung A; Fazal A; Shultz MD; Stams T
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Feb; 68(Pt 2):115-8. PubMed ID: 22297980
[TBL] [Abstract][Full Text] [Related]
48. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
Cheng H; Li X; Wang C; Chen Y; Li S; Tan J; Tan B; He Y
Cancer Lett; 2019 Feb; 443():80-90. PubMed ID: 30472184
[TBL] [Abstract][Full Text] [Related]
50. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
51. USP25 regulates Wnt signaling by controlling the stability of tankyrases.
Xu D; Liu J; Fu T; Shan B; Qian L; Pan L; Yuan J
Genes Dev; 2017 May; 31(10):1024-1035. PubMed ID: 28619731
[TBL] [Abstract][Full Text] [Related]
52. Tankyrase Inhibition Attenuates Cardiac Dilatation and Dysfunction in Ischemic Heart Failure.
Wang H; Segersvärd H; Siren J; Perttunen S; Immonen K; Kosonen R; Chen YC; Tolva J; Laivuori M; Mäyränpää MI; Kovanen PT; Sinisalo J; Laine M; Tikkanen I; Lakkisto P
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077457
[TBL] [Abstract][Full Text] [Related]
53. Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy.
Li X; Han H; Zhou MT; Yang B; Ta AP; Li N; Chen J; Wang W
Cell Rep; 2017 Jul; 20(3):737-749. PubMed ID: 28723574
[TBL] [Abstract][Full Text] [Related]
54. Screening and structural analysis of flavones inhibiting tankyrases.
Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L
J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272
[TBL] [Abstract][Full Text] [Related]
55. Exploring the effect of PARP-1 flexibility in docking studies.
Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
[TBL] [Abstract][Full Text] [Related]
56. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Johannes JW; Almeida L; Daly K; Ferguson AD; Grosskurth SE; Guan H; Howard T; Ioannidis S; Kazmirski S; Lamb ML; Larsen NA; Lyne PD; Mikule K; Ogoe C; Peng B; Petteruti P; Read JA; Su N; Sylvester M; Throner S; Wang W; Wang X; Wu J; Ye Q; Yu Y; Zheng X; Scott DA
Bioorg Med Chem Lett; 2015 Dec; 25(24):5743-7. PubMed ID: 26546219
[TBL] [Abstract][Full Text] [Related]
57. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
58. Discovery of Novel Tankyrase Inhibitors through Molecular Docking-Based Virtual Screening and Molecular Dynamics Simulation Studies.
Berishvili VP; Kuimov AN; Voronkov AE; Radchenko EV; Kumar P; Choonara YE; Pillay V; Kamal A; Palyulin VA
Molecules; 2020 Jul; 25(14):. PubMed ID: 32664504
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and biological activity evaluation of new tankyrase-2 directed inhibitors.
Zhang X; Pang W; Li T; Lin T; Yuan J; Xu S
Chem Biol Drug Des; 2024 Jan; 103(1):e14360. PubMed ID: 37814809
[TBL] [Abstract][Full Text] [Related]
60. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
